Drug And Gene Delivery Devices Market Report 2026

Drug And Gene Delivery Devices Market Overview

• Drug And Gene Delivery Devices market size has reached to $0.67 billion in 2025 • Expected to grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: The Increasing Adoption Of Gene Therapy Propelling The Growth Of The Drug And Gene Delivery Devices Market • Market Trend: The Role Of AI Technology In Advancing Treatment Solutions • North America was the largest region in 2025.

What Is Covered Under Drug And Gene Delivery Devices Market?

Drug and gene delivery devices are tools designed to transport pharmaceuticals or genetic material into the body for therapeutic purposes, enabling targeted treatment of diseases at the molecular level with enhanced precision and efficacy. These devices are crucial in advancing personalized medicine by ensuring controlled release and optimal delivery of therapeutic agents to specific cells or tissues, minimizing side effects, and maximizing treatment effectiveness. The main vector types of drug and gene delivery devices are viral and non-viral. Viral gene delivery involves using genetically engineered viruses to deliver therapeutic genes into target cells. The method is in situ and ex vivo, and the various routes of administration are oral, inhalation, transdermal, injectable, ocular, nasal, and topical.

What Is The Drug And Gene Delivery Devices Market Growth Forecast?

The drug and gene delivery devices market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to technological advancements in viral and non-viral vectors, expansion of personalized medicine and gene therapy applications, increasing regulatory approvals for innovative delivery systems, rising adoption of nanomedicine and LNPs, integration of digital monitoring and smart delivery platforms. Major trends in the forecast period include growth of targeted drug and gene therapies, rising adoption of nanoparticle-based delivery systems, increasing use of viral vectors for gene therapy, expansion of injectable and non-invasive delivery methods, focus on personalized medicine and controlled release technologies.

Global Drug And Gene Delivery Devices Market Segmentation

1) By Vector: Viral, Non-viral 2) By Method: In Situ, Ex Vivo 3) By Route Of Administration: Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical Subsegments: 1) By Viral: Adenovirus Vectors, Lentivirus Vectors, Adeno-Associated Virus (AAV) Vectors, Herpes Simplex Virus (HSV) Vectors, Retrovirus Vectors, Baculovirus Vectors, Vaccinia Virus Vectors, Sendai Virus Vectors 2) By Non-Viral: Lipid Nanoparticles (LNP), Polymeric Nanoparticles, Liposomes, Dendrimers, Naked DNA/RNA Delivery, Electroporation-Based Delivery Systems, Nanoparticle-Based Delivery Systems, Polymer Micelles And Hydrogels.

What Is The Driver Of The Drug And Gene Delivery Devices Market?

The increasing adoption of gene therapy is expected to propel the growth of the drug and gene delivery devices market going forward. Gene therapy is a medical technique that involves the introduction, removal, or alteration of genetic material within a patient's cells to treat or prevent disease. Gene therapy demand is rising due to its potential to cure genetic disorders and chronic diseases at their root causes, offering transformative treatment options where conventional therapies fall short. Drug and gene delivery devices are essential in gene therapy for precise targeting and controlled release of therapeutic genes, enhancing treatment efficacy. For instance, in January 2025, according to the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported that in Q4 2024 number of pre-registration gene therapy programs experienced the largest increase in more than a year, rising by 83% compared to Q3 2024. Therefore, the increasing adoption of gene therapy is driving the growth of the drug and gene delivery devices industry.

Key Players In The Global Drug And Gene Delivery Devices Market

Major companies operating in the drug and gene delivery devices market are Medtronic plc, Moderna Inc., Halozyme Therapeutics Inc., Uniqure NV, Intellia Therapeutics Inc., Voyager Therapeutics Inc., sfm medical devices GmbH, Inovio Pharmaceuticals Inc., GenSight Biologics S.A., CRISPR Therapeutics, Pfizer Inc., Novartis AG, Becton Dickinson and Company, Shanghai Sunway Biotech Co Ltd, Epeius Biotechnologies Corporation, SiBiono GeneTech Co Ltd, F Hoffmann‑La Roche Ltd, Baxter International, B Braun Melsungen, Terumo Corporation, ICU Medical, Stevanato Group, Gerresheimer AG, Ypsomed, SHL Medical

Global Drug And Gene Delivery Devices Market Trends and Insights

Major companies operating in the drug and gene delivery devices market are focusing on developing advanced products, such as artificial intelligence (AI) technology, to gain a competitive edge in the market. Artificial intelligence (AI) technology in drug delivery refers to the application of AI techniques and algorithms to improve the efficiency, precision, and effectiveness of drug delivery systems. For instance, in December 2023, Envoya Inc., a US-based developer of polymer-based nanoparticles for targeted delivery, launched an innovative gene therapy drug delivery platform. This platform combines biopolymer-nanoparticles with artificial intelligence (AI) to address significant limitations in current gene therapy technologies, such as viral vectors and lipid nanoparticles. The platform aims to overcome the limitations of existing gene therapy delivery technologies, which have been restricted by safety concerns, limited payload capacities, and limited tissue targeting.

What Are Latest Mergers And Acquisitions In The Drug And Gene Delivery Devices Market?

In January 2025, F. Hoffmann-La Roche Ltd, a Switzerland-based pharmaceutical company, acquired Poseida Therapeutics Inc. for an amount of $1.5 billion. With this acquisition, it aims to enhance its oncology pipeline and expand its capabilities in allogeneic CAR-T cell therapies for blood cancers, solid tumors, and autoimmune diseases. Poseida Therapeutics Inc. is a US-based company that specializes in providing complex immune cell therapies, including genetically modified CAR-T therapies targeting cancer and autoimmune disorders.

Regional Outlook

North America was the largest region in the drug and gene delivery devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Drug And Gene Delivery Devices Market?

The drug and gene delivery devices market consists of sales of microspheres and microneedles, electroporation devices, bio adhesive systems, and gene therapy vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.